Dry Eye Disease Market Synopsis:
\nDry Eye Disease Market Size Was Valued at USD 6.5 Billion in 2023, and is Projected to Reach USD 9.4 Billion by 2032, Growing at a CAGR of 4.2% From 2024-2032.
\nKeratoconjunctivitis sicca, or Dry Eye Disease (DED), is essentially an inadequate tear film or a failure to maintain an adequate tear film, along with inflammation and damage to the ocular surface. They may cause manifestations such as pain, burning, and loss of vision; imposing an impact on the daily life. This condition may be can be chronic and ranges from being merely an annoyance to a debilitating painful state. @DataDreamers, DED sources may include aging, hormonal fluctuations, environmental factors, and computer usage \u2013 which hampers blinking and therefore hinders tear production.<\/p>\n
The Dry Eye Disease market has grown remarkably over the years because of the growing incidence of the disease across the entire globe primarily due to an aging populace, changing climate, and increased screen time. Currently, the World Health Organization estimates the increase of dry eye disease prevalence among the population of the developed as well as developing countries at millions. Higher understanding of people on the importance of eye health and the growing incidence rates are the major factors that foster the need for efficient treatment thereby leading to enhanced market for DED.<\/p>\n
The market is also witnessing new methods of curing for eye afflictions with new formulations of artificial tears and prescriptive eye drops right through to new surgical style procedures out there. New therapies, including cyclosporine and lifitegrast, are commerciallyized while research in the biologics and regenerative medicine fronts continue to add muscle to it. Furthermore, the presence of generic products in this market along with the strong emphasis in research and development by market players the global market is shifting to optimism in terms of growth.<\/p>\n
Dry Eye Disease Market Trend Analysis:
\nRising Digital Screen Use Driving Market Trend<\/p>\n
This has emerged as one of the major growth-driving factors affecting the Dry Eye Disease industry where the prevalence of the conditions is, most likely due to the increased application of digital devices. Thanks to technological advancement that has seen the use of smart phones, computers and tablets as working tools, learning aids, and entertainment devices; eye strain is becoming more and more evident. It reduces the number of blinks as it takes approximately fifteen minutes for the eyelid to blink open the tear film evenly across the eyes. This has led to increased prevalence of dry eyes; this is especially, so in the youthful population that spends most of their time staring at computer screens. For this reason, there is increasing demand for treatment, both for existing and new patients, augmenting the market for DED therapies even further.
\nIncreasing Focus on Advanced Therapies Presents an Opportunity<\/p>\n
They identified the increasing focus on creating superior treatment solutions for Dry Eye Disease as a new market driver for players. Recent advances in the subject include the discovery of biologics, stem cell therapy, and new types of anti-inflammatory medication that offer fresh possibilities for treating chronic and serious forms of DED. Similarly, rising investment in diagnosable medicine technology like, personalized medicine and gene therapy, in case of nonresponder patients to traditional therapeutics again offers a vast growth prospect. Increased healthcare facilities especially in the developing countries continues to increase uptake of these superior techniques\u2014a favorable market condition for DED market players.
\nDry Eye Disease Market Segment Analysis:
\nDry Eye Disease Market is Segmented on the basis of Product, Distribution Channel, and Region
\nBy Product, Artificial Tears segment is expected to dominate the market during the forecast period<\/p>\n
Despite the ease of availability and accessibility, and the continuous demand for the products in the market, artificial tears, as a product segment, is projected to form the majority of the Dry Eye Disease market during the forecast period. Instant relief that artificial tears offer come from the fact that they act as eye lubricants to complement the natural tear film and reduce dryness. Due to their convenience and variety of formulas, these OTC medicines are purchased frequently by buyers and they are still cheaper than those that require prescription. In addition, the manufacturers are working hard to enhance their products through adding new active ingredients like hyaluronic acid and other with a view to providing long-lasting relief \u2013 all these explain why this segment is dominant. The growing interest in eye\u2019s health as well as the shift in consumers\u2019 attitude towards self-treatment are also anticipated to unlock the artificial tears segment.
\nBy Distribution Channel, Hospital Pharmacies segment expected to held the largest share <\/p>\n
Out of the distribution channels, the hospital pharmacy will have the largest market share, including in the advanced treatments of severe Dry Eye Disease. Many customers trust independent hospital pharmacies such as prescription eye drops, cyclosporine, and other anti-inflammatory products. These are factors such as availability of specialty eye care products and healthcare services of a specialist who will recommend the products to the patient makes hospital pharmacy more appealing to patients than the other channels of distribution. <\/p>\n
Additionally, growth in the number of hospital and specialized ophthalmic centers in both developed and developing countries is also contributing to the growth in the share of hospital pharmacy in this market. The supply of prescription-based products is well controlled, and hospital pharmacies are generally capable of meeting the : needs represented by such requirements, which is why hospital pharmacies retain the leading position.
\nDry Eye Disease Market Regional Insights:
\nNorth America is Expected to Dominate the Market Over the Forecast period <\/p>\n
It is study that North America is estimated to be the largest market for Dry Eye Disease in 2023 owing to its services, availability of enhanced healthcare systems, as well as the growing incidence of Dry Eye Disease. Lifestyle eye conditions like digital eye strain and existing large elderly population boosts this regions market for dry eye products. The presence of most of the key players involved in research and development activities required in the manufacture of new drugs also aids market growth. Moreover, appropriate reimbursement policies of treatments and powerful distribution channels in United States and Canada improve the access of both medicinal and non-medicinal treatments. Based on the research forecasted for 2023, North America alone is likely to account for more than 40% of the entire market, especially through the US.
\nActive Key Players in the Dry Eye Disease Market:<\/p>\n
Alcon (Switzerland)<\/p>\n
Allergan (Ireland)<\/p>\n
Bausch Health Companies Inc. (Canada)<\/p>\n
Hoffmann-La Roche Ltd. (Switzerland)<\/p>\n
Johnson & Johnson (U.S.)<\/p>\n
Lumenis (Israel)<\/p>\n
Mitotech S.A. (Luxembourg)<\/p>\n
Novartis AG (Switzerland)<\/p>\n
Otsuka Pharmaceutical Co., Ltd. (Japan)<\/p>\n
Pfizer Inc. (U.S.)<\/p>\n
Regeneron Pharmaceuticals Inc. (U.S.)<\/p>\n
Santen Pharmaceutical Co., Ltd. (Japan)<\/p>\n
Sentiss Pharma Pvt. Ltd. (India)<\/p>\n
Sun Pharmaceutical Industries Ltd. (India)<\/p>\n
Teva Pharmaceutical Industries Ltd. (Israel)<\/p>\n
Other Active Players<\/p>\n","protected":false},"excerpt":{"rendered":"
Keratoconjunctivitis sicca, or Dry Eye Disease (DED), is essentially an inadequate tear film or a failure to maintain an adequate tear film, along with inflammation and damage to the ocular surface. They may cause manifestations such as pain, burning, and loss of vision; imposing an impact on the daily life. This condition may be can be chronic and ranges from being merely an annoyance to a debilitating painful state. @DataDreamers, DED sources may include aging, hormonal fluctuations, environmental factors, and computer usage \u2013 which hampers blinking and therefore hinders tear production.<\/p>\n","protected":false},"featured_media":24088,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[194],"product_tag":[],"class_list":["post-26897","product","type-product","status-publish","has-post-thumbnail","product_cat-healthcare-life-sciences","first","instock","virtual","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n